Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)

1. Garcia Campelo, M.R.
2. Lin, H.M.
3. Zhu, Y.
4. Pérol, M.
5. Jahanzeb, M.
6. Popat, S.
7. Zhang, P.
8. Camidge, D.R.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.LUNGCAN.2021.03.005 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus